Key result
Pembrolizumab treatment resulted in a sustained clinical and radiological remission in a heavily pre-treated patient with recurrent metastatic Ewing sarcoma.
Why the study?
Does pembrolizumab improve clinical and radiological outcomes in a patient with recurrent metastatic Ewing sarcoma?
Case Report (n=1)
No
Does pembrolizumab improve clinical and radiological outcomes in a patient with recurrent metastatic Ewing sarcoma?
This first reported case demonstrates the potential efficacy of PD-1 blockade (pembrolizumab) in achieving clinical and radiological remission in heavily pre-treated recurrent metastatic Ewing sarcoma.
Hypothesis-generating for PD-1 blockade in recurrent metastatic Ewing sarcoma; prospective trials needed before clinical adoption.
BACKGROUND: Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor. CASE PRESENTATION: In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade. CONCLUSIONS: To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
No takes yet. Share an insight, caveat, or question.
McCaughan et al. (2016) conducted a case report in Recurrent disseminated Ewing sarcoma (n=1). Pembrolizumab was evaluated on Clinical and radiological response. Pembrolizumab treatment resulted in a sustained clinical and radiological remission in a heavily pre-treated patient with recurrent metastatic Ewing sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: